Thomas Jefferson University

Oncology & Cancer

Novel cancer vaccine approach for brain tumors

Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months (compared to 4 months without treatment). Researchers at Thomas Jefferson ...

Medications

New drug target to treat pain from visceral organs

An approved drug for chronic constipation also relieves the pain associated with that condition. New research by Scott Waldman, MD, Ph.D., chair of pharmacology, physiology and cancer biology at Jefferson, demonstrates that ...

Alzheimer's disease & dementia

Study prevents cognitive decline in older blacks with memory loss

With nearly twice the rate of dementia as whites, blacks are at a higher risk for developing diseases like Alzheimer's, but there has been little research on how to reduce this racial health disparity. A new study in black ...

Neuroscience

Restoring nerve-muscle communication in ALS

Patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, lose muscle control as nerve cells or neurons in the brain and spinal cord degenerate and can no longer send signals to muscles. Previous ...

Medical research

A way to make asthma drugs last longer

For many, inhalers are a sort of miracle drug. From gasping for air one minute, to breathing normally the next, patients can experience significant relief after one or two puffs. What few people realize is that these life-saving ...

Neuroscience

New approach for treating ALS

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disease that primarily kills motor neurons, leading to paralysis and death 2 to 5 years from diagnosis. Currently ALS has no ...

page 10 from 40